FY2026 Earnings Forecast for Accuray Issued By Roth Capital

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Equities research analysts at Roth Capital upped their FY2026 earnings per share (EPS) estimates for Accuray in a research report issued to clients and investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings per share of $0.11 for the year, up from their previous estimate of $0.08. The consensus estimate for Accuray's current full-year earnings is $0.01 per share.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The business had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. During the same quarter in the prior year, the business posted ($0.03) EPS.

Separately, StockNews.com lowered Accuray from a "buy" rating to a "hold" rating in a research report on Friday, November 15th.

Accuray Stock Performance

ARAY traded up $0.04 on Friday, reaching $1.93. 638,787 shares of the stock were exchanged, compared to its average volume of 662,232. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The company's 50-day moving average price is $1.85 and its 200 day moving average price is $1.83. The firm has a market capitalization of $194.10 million, a PE ratio of -11.21 and a beta of 1.40. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $3.05.

Institutional Trading of Accuray

A number of hedge funds have recently modified their holdings of ARAY. The Manufacturers Life Insurance Company boosted its position in Accuray by 13.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 5,273 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Accuray by 9.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider's stock worth $181,000 after buying an additional 6,583 shares in the last quarter. Renaissance Technologies LLC grew its position in Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider's stock valued at $5,118,000 after buying an additional 7,500 shares during the period. Bank of New York Mellon Corp increased its holdings in Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider's stock valued at $509,000 after buying an additional 8,864 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 15,209 shares during the period. Hedge funds and other institutional investors own 64.08% of the company's stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.